Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.54 |
| ▸ | PYGL | P06737 | 1/20 | 0.51 |
| ▸ | CA1 | P00915 | 4/20 | 0.50 |
| ▸ | CA2 | P00918 | 4/20 | 0.50 |
| ▸ | CA12 | O43570 | 3/20 | 0.50 |
| ▸ | CA7 | P43166 | 3/20 | 0.50 |
| ▸ | CA9 | Q16790 | 3/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.50 |
| ▸ | XDH | P47989 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | ATM | Q13315 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14820365 | 0.86 | PRKCI (0.59) | MAPTKMT2ACA1CA2CA12 | |
| SCHEMBL2343153 | 0.86 | CA12 (0.65) | KMT2APYGLCA1CA2CA12 | |
| SCHEMBL25073578 | 0.84 | MAPT (0.58) | MAPTKMT2APYGLCA1CA2 | |
| SCHEMBL761046 | 0.84 | MAPT (0.58) | MAPTKMT2APYGLCA1CA2 | |
| SCHEMBL14433132 | 0.84 | LRRK2 (0.56) | MAPTKMT2APYGLCA1CA2 | |
| SCHEMBL15693330 | 0.83 | ALDH1A1 (0.62) | MAPTKMT2APYGLKDM4EMEN1 | |
| SCHEMBL23970386 | 0.82 | NOTUM (0.52) | MAPTKMT2APYGLCA1CA2 | |
| SCHEMBL28261209 | 0.82 | MAPT (0.48) | MAPTKMT2APYGLCA1CA2 | |
| SCHEMBL25072710 | 0.81 | MAPT (0.59) | MAPTKMT2APYGLCA1CA2 | |
| SCHEMBL156940 | 0.81 | MAPT (0.55) | MAPTKMT2APYGLCA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118047732-A | Preparation process of dabigatran etexilate special intermediate | 江苏阿尔法集团盛基药业(宿迁)有限公司 | 2024-05-17 | — | — | CN | disclosed |
| CN-117843617-A | Intermediate compound of dabigatran etexilate and synthesis method thereof | 江苏阿尔法药业股份有限公司 | 2024-04-09 | — | — | CN | disclosed |
| CN-116003384-A | Synthesis method of dabigatran etexilate important intermediate | 宿迁盛基医药科技有限公司 | 2023-04-25 | — | — | CN | disclosed |
| WO-2020071911-A1 | PHOTORESPONSIVE NUTLIN DERIVATIVES AND USES THEREOF | RIJKSUNIVERSITEIT GRONINGEN (NL) | 2020-04-09 | — | — | WO | disclosed |
| EP-1568688-B1 | THERAPEUTIC AGENT FOR RESPIRATORY DISEASE CONTAINING 4-HYDROXYPIPERIDINE DERIVATIVE AS ACTIVE INGREDIENT | MOCHIDA PHARM CO LTD (JP) | 2011-08-31 | — | — | EP | disclosed |
| EP-1568688-B1 | THERAPEUTIC AGENT FOR RESPIRATORY DISEASE CONTAINING 4-HYDROXYPIPERIDINE DERIVATIVE AS ACTIVE INGREDIENT | MOCHIDA PHARM CO LTD (JP) | 2011-08-31 | — | — | EP | disclosed |
| US-7494987-B2 | Agent for treating respiratory diseases containing 4-hydroxypiperidine derivative as active ingredient | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2009-02-24 | — | — | US | disclosed |
| US-7494987-B2 | Agent for treating respiratory diseases containing 4-hydroxypiperidine derivative as active ingredient | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2009-02-24 | — | — | US | disclosed |
| US-20060040985-A1 | Therapeutic agent for treating respiratory diseases containing 4-hydroxypiperidine derivative as active ingredient | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2006-02-23 | — | — | US | disclosed |
| EP-1568688-A1 | THERAPEUTIC AGENT FOR RESPIRATORY DISEASE CONTAINING 4-HYDROXYPIPERIDINE DERIVATIVE AS ACTIVE INGREDIENT | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2005-08-31 | — | — | EP | disclosed |
| US-6294557-B1 | ANALGESIC AT CENTRAL NERVOUS SYSTEM IN THE MAMMALIAN SUBJECT. ALSO, THESE COMPOUNDS ARE INFLAMMATORY PAIN CAUSED, FOR EXAMPLE BY BURNS (INDUCED BY A CONTACT WITH HEAT, ACID OR THE OTHER RHEUMATISM OR THE LIKE, IN THE SAID SUBJECT. | PFIZER INC. | 2001-09-25 | — | — | US | disclosed |
| US-6294569-B2 | ANALGESIC AT CENTRAL NERVOUS SYSTEM IN THE MAMMALIAN SUBJECT. ALSO, THESE COMPOUNDS ARE INFLAMMATORY PAIN CAUSED, FOR EXAMPLE BY BURNS (INDUCED BY A CONTACT WITH HEAT, ACID OR THE OTHER RHEUMATISM OR THE LIKE, IN THE SAID SUBJECT. | PFIZER INC. | 2001-09-25 | — | — | US | disclosed |
| US-20010020024-A1 | Pyrrolidinyl and pyrrolinyl ethylamine compounds as kappa agonists | ITO FUMITAKA (JP) | 2001-09-06 | — | — | US | disclosed |
| US-20010014683-A1 | Analgesics; side effect reduction | ITO FUMITAKA (JP) | 2001-08-16 | — | — | US | disclosed |
| US-20010011091-A1 | Analgesics | ITO FUMITAKA (JP) | 2001-08-02 | — | — | US | disclosed |
| US-20010009921-A1 | Less tendency to cause drug dependency, analgesic, anesthetic, anti-inflammatory or neuroprotective agent; subtype of opoid receptor | ITO FUMITAKA (JP) | 2001-07-26 | — | — | US | disclosed |
| US-20010008890-A1 | Useful as analgesic, anesthetic, antiinflammatory or neuroprotective agents and in treatment of arthritis, stroke, bowel disease | ITO FUMITAKA (JP) | 2001-07-19 | — | — | US | disclosed |
| US-6201007-B1 | OPIOID KAPPA RECEPTOR AGONISTS; ANALGESICS, ANESTHETICS, NEUROPROTECTIVE AND ANTIINFLAMMATORY AGENTS; STROKES, GASTROINTESTINAL DISORDERS | PFIZER INC. | 2001-03-13 | — | — | US | disclosed |
| EP-0934264-A1 | PYRROLIDINYL AND PYRROLINYL ETHYLAMINE COMPOUNDS AS KAPPA AGONISTS | PFIZER INC. (US) | 1999-08-11 | — | — | EP | disclosed |
| WO-1998012177-A1 | PYRROLIDINYL AND PYRROLINYL ETHYLAMINE COMPOUNDS AS KAPPA AGONISTS | PFIZER INC. (JP) | 1998-03-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010009921-A1 | Less tendency to cause drug dependency, analgesic, anesthetic, anti-inflammatory or neuroprotective agent; subtype of opoid receptor | OPRL1, OPRD1, OPRK1 | MAPT 1579/4885KMT2A 1358/4885PYGL 4370/4885 |
| US-20010011091-A1 | Analgesics | OPRL1, OPRK1, OPRD1 | MAPT 2858/4885KMT2A 391/4885PYGL 3487/4885 |
| US-20060040985-A1 | Therapeutic agent for treating respiratory diseases containing 4-hydroxypiperidine derivative as active ingredient | BRD7, RBBP7, NR0B1 | MAPT 4685/4885KMT2A 2822/4885PYGL 4190/4885 |
| US-20010020024-A1 | Pyrrolidinyl and pyrrolinyl ethylamine compounds as kappa agonists | OPRK1, OPRL1, OPRD1 | MAPT 3756/4885KMT2A 678/4885PYGL 4391/4885 |
| US-20010014683-A1 | Analgesics; side effect reduction | OPRL1, OPRK1, OPRD1 | MAPT 3404/4885KMT2A 418/4885PYGL 3387/4885 |
| US-20010008890-A1 | Useful as analgesic, anesthetic, antiinflammatory or neuroprotective agents and in treatment of arthritis, stroke, bowel disease | OPRL1, NAP1L1, OPRK1 | MAPT 2088/4885KMT2A 1560/4885PYGL 3400/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.